Simoctocog alfa - Octapharma
Alternative Names: Factor VIII recombinant- Octapharma; Human-cell-line-recombinant-human-factor-VIII-Octapharma; Human-cl rhFVIII - Octapharma; Nuwiq; rFactor-VIII-Octapharma ; rFVIII-OctapharmaLatest Information Update: 18 Jan 2024
At a glance
- Originator Octapharma
- Developer Cardinal Health; Emory University; Genentech; Octapharma
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Polyethylene glycols; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilia A
Most Recent Events
- 05 Jan 2024 Emory University and Genentech withdraws phase III trial for Haemophilia A (Treatment-naive, In adolescents, In adults, In children) in USA (IV) prior to enrollment due to slow enrollment and study site startup (NCT04030052)
- 09 Dec 2023 Updated efficacy data from the phase III NuProtect trial in haemophilia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 05 Dec 2022 Octapharma plans a phase III NuPOWER trial for Haemophilia A (Treatment-experienced) in 2023